Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”As I close the chapter on ASH2025, I’m energized by the conversations happening across the hematology community.
Being on the ground at conferences like ASH is so important for our work in rare blood disorders.
It’s where we connect with the researchers advancing the science, the clinicians treating patients every day, and the advocates representing the communities we serve – a convergence of those who have a real stake in the research, the data, and the outcomes.
The breadth of scientific innovation presented this year was impressive.
I heard a lot about the potential of multi-immune modulation as an approach to rare autoimmune conditions like Immune Thrombocytopenia (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and Sickle Cell Disease (SCD).
While hemophilia remains core to our mission, I’ve enjoyed expanding our scientific discussions with healthcare providers who manage patients with Complex Immune Dysregulation (CID) conditions.
There’s clearly significant room for improvement for these patients who often have no treatments approved specifically for their condition.
These face-to-face conversations remind us why we do what we do.
A red thread throughout all my discussions was how our work translates to real impact in patients’ daily lives.
Hearing directly from the hematology community about the challenges they face, the progress being made, and the work still ahead helps inform our path forward.
What were some of your key learnings from the meeting?”
Stay updated with Hemostasis Today.
-
Oct 26, 2026, 13:57Gladys Delancey: Spotting the Warning Signs of Vein Disease
-
Oct 26, 2026, 13:36Kefah Mokbel: Targeted Breast Cancer Therapies Linked to Increased Thrombotic Risk
-
Oct 26, 2026, 13:32Jorge Enrique: Beyond Fibrin Targeting New Strategies for Thrombolysis
-
Oct 26, 2026, 13:23Priya Sriskandarajah: Treatment Challenges in Elderly and Frail Patients with Philadelphia-Negative MPNs
-
Oct 26, 2026, 12:48Milica Kuzmanovska: Latest Updates in PV, ET, and Myelofibrosis Management
-
Oct 26, 2026, 12:38Hytham Abu Aagla: Daratumumab and Transfusion Compatibility
-
Oct 26, 2026, 10:17Pankaj K.: Genetic Hemolytic Anemias Common Types, Symptoms and Long-Term Management
-
Oct 26, 2026, 10:09Christopher Robinson: Anemia and Postpartum Transfusion Rates at Different Blood Loss Thresholds After Vaginal Delivery
-
Oct 26, 2026, 09:54Hussnain Javaid: IV Iron During Active Bacterial Infection Reassessing the Risks and Benefits